Provided according to some embodiments of the invention are topical gels that may release nitric oxide. Also provided are methods of using such topical gels in the treatment of wounds and other skin ailments. The topical gels comprise diazeniutndiolate-functionalized polysiloxane macromolecules.
대표청구항▼
1. A topical composition comprising nitric oxide-releasing polysiloxane macromolecules and a hydrophobic, non-aqueous gel base, the hydrophobic, non-aqueous gel base comprising mineral oil, wherein the nitric oxide (NO) storage per gram is in a range of 100 nmol NO/g to 1 mmol NO/g of the topical co
1. A topical composition comprising nitric oxide-releasing polysiloxane macromolecules and a hydrophobic, non-aqueous gel base, the hydrophobic, non-aqueous gel base comprising mineral oil, wherein the nitric oxide (NO) storage per gram is in a range of 100 nmol NO/g to 1 mmol NO/g of the topical composition and at least 70% of NO of the nitric oxide-releasing polysiloxane macromolecule remains in the topical composition two days after initial formulation when the topical composition is stored at room temperature. 2. The topical composition of claim 1, wherein the concentration of the nitric oxide-releasing polysiloxane macromolecules is in a range of 0.1% to 20% by weight of the topical composition. 3. The topical composition of claim 1, wherein the hydrophobic, non-aqueous gel base is a silicone gel. 4. The topical composition of claim 1, wherein the hydrophobic, non-aqueous gel base comprises petrolatum. 5. The topical composition of claim 1, wherein mineral oil is present in the topical composition at a concentration in a range of 10% to 90% by weight of the topical composition. 6. The topical composition of claim 1, wherein the hydrophobic, non-aqueous gel base comprises gel excipients and the nitric oxide-releasing polysiloxane macromolecules and gel excipients have an octanol/water partition coefficient in a range of 0.1 to 7. 7. The topical composition of claim 1, wherein the nitric oxide-releasing polysiloxane macromolecules have a hydrodynamic radius in a range of 1000 nm to 10 microns. 8. The topical composition of claim 1, wherein the nitric oxide-releasing polysiloxane macromolecules have a hydrodynamic radius in a range of 1 nm to 100 nm. 9. The topical composition of claim 1, further comprising an anti-acne agent, antimicrobial agent, benzoyl peroxide, or a corticosteroid. 10. A topical composition comprising nitric oxide-releasing polysiloxane macromolecules and a hydrophilic gel base, the hydrophilic gel base comprising an alcohol, wherein the nitric oxide (NO) storage per gram is in a range of 100 nmol NO/g to 1 mmol NO/g of the topical composition and at least 70% of NO of the nitric oxide-releasing polysiloxane macromolecule remains in the topical composition two days after initial formulation when the topical composition is stored at room temperature. 11. The topical composition of claim 10, wherein the concentration of the nitric oxide-releasing polysiloxane macromolecules is in a range of 0.1% to 20% by weight of the topical composition. 12. The topical composition of claim 10, further comprising isopropyl alcohol at a concentration in a range of 60% to 90% by weight of the topical composition; and hydroxypropyl cellulose at a concentration in a range of 0.75% to 2.5% by weight of the topical composition. 13. The topical composition of claim 10, wherein the hydrophilic gel base comprises gel excipients and the nitric oxide-releasing polysiloxane macromolecules and the gel excipients have an octanol/water partition coefficient in a range of −2 to 0. 14. The topical composition of claim 10, wherein the nitric oxide-releasing polysiloxane macromolecules have a hydrodynamic radius in a range of 1000 nm to 10 microns. 15. The topical composition of claim 10, wherein the nitric oxide-releasing polysiloxane macromolecules have a hydrodynamic radius in a range of 1 nm to 100 nm. 16. The topical composition of claim 10, further comprising a retinoid, antimicrobial agent, benzoyl peroxide, or a corticosteroid. 17. A method of treating a wound comprising applying the topical composition of claim 1. 18. A method of treating a wound comprising applying the topical composition of claim 10. 19. A method of treating a burn comprising applying the topical composition of claim 1. 20. A method of treating acne comprising applying the topical composition of claim 1. 21. A method of treating acne comprising applying the topical composition of claim 10. 22. The topical composition of claim 1, wherein at least 80% of NO of the nitric oxide-releasing polysiloxane macromolecule remains in the topical composition two days after initial formulation when the topical composition is stored at room temperature. 23. The topical composition of claim 10, wherein at least 80% of NO of the nitric oxide-releasing polysiloxane macromolecule remains in the topical composition two days after initial formulation when the topical composition is stored at room temperature. 24. The topical composition of claim 1, wherein the topical composition comprises one or more hydrophobic components and the total concentration of the one or more hydrophobic components present in the topical composition is at least 49% by weight of the topical composition. 25. The topical composition of claim 1, wherein the topical composition comprises one or more hydrophobic components and the total concentration of the one or more hydrophobic components present in the topical composition is at least 80% by weight of the topical composition. 26. The topical composition of claim 10, wherein the alcohol is present in the topical composition at a concentration of at least 60% by weight of the topical composition. 27. The topical composition of claim 10, wherein the alcohol is present in the topical composition at a concentration in a range of 60% to 90% by weight of the topical composition. 28. The topical composition of claim 10, wherein the alcohol is isopropyl alcohol. 29. The topical composition of claim 10, wherein the hydrophilic gel base further comprises hydroxypropyl cellulose. 30. The topical composition of claim 29, wherein the hydroxypropyl cellulose is present at a concentration in a range of 0.75% to 2.5% by weight of the composition. 31. The topical composition of claim 10, wherein the topical composition is non-aqueous.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (271)
Benjamin, Nigel; Dougall, Hamish; Ormerod, Anthony, Acidified nitrite as an antimicrobial agent.
Saavedra Joseph E. (Thurmont MD) Keefer Larry K. (Bethesda MD) Roller Peter P. (Rockville MD) Akamatsu Miki (Rockville MD), Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of trea.
Saavedra Joseph E. ; Keefer Larry K. ; Roller Peter P. ; Akamatsu Miki, Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same.
Michal,Eugene T; Hossainy,Syed F A; Consigny,Paul M, Coatings for implantable medical devices incorporating chemically-bound polymers and oligomers of L-arginine.
Garvey David S. ; Schroeder Joseph D. ; Saenz de Tejada Inigo,ESX, Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use.
Guthikonda Ravindra N. (Edison NJ) Grant Stephan K. (Robbinsville NJ) Maccoss Malcolm (Freehold NJ) Shah Shrenik K. (Metuchen NJ) Shankaran Kothandaraman (Kendall Park NJ) Caldwell Charles G. (Scotch, Cyclic amidine analogs as inhibitors of nitric oxide synthase.
Girten Beverly E. ; Andalibi Ali ; Basu Amaresh ; Fagan Patrick ; Houghten Richard A. ; Loullis Costas C. ; Omholt Paul ; Tuttle Ronald R. ; Suto Mark J. ; Weber Patricia A., Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels.
Girten Beverly E. ; Houghten Richard A. ; Loullis Costas C. ; Suto Mark J. ; Tuttle Ronald R., Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels.
Girten Beverly E. ; Houghten Richard A. ; Loullis Costas C. ; Suto Mark J. ; Tuttle Ronald R., Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels.
Hult Anders (Tby SEX) Malmstrom Eva (Bandhagen SEX) Johansson Mats (Stockholm SEX) Srensen Kent (Perstorp SEX), Dendritic macromolecule and process for preparation thereof.
Adams, Michael A.; Graham, Charles H.; Heaton, Jeremy P. W.; Postovit, Lynne-Marie, Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype.
Graham, Charles H.; Postovit, Lynn-Marie; Adams, Michael A.; Heaton, Jeremy P. W., Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype.
Bianchi Marina (Milan ITX) Cerami Anthony (Shelter Island NY) Tracey Kevin J. (Old Greenwich CT) Ulrich Peter (Old Tappan NJ), Guanylhydrazones and their use to treat inflammatory conditions.
Charles G. Caldwell ; Malcolm Maccoss ; William K. Hagmann ; Shrenik K. Shah ; Kothandaraman Shankaran ; Karla L. Furman, Hexahydro-5-imino-1,4-1,4-thiazepine derivatives as inhibitors of nitric oxide synthases.
Caldwell Charles G. ; Hagmann William K. ; Maccoss Malcolm ; Shah Shrenik K. ; Shankaran Kothandaraman ; Furman Karla L., Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases.
Fitzhugh, Anthony L.; Cafferata, Robert; Keefer, Larry K., Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use.
Fitzhugh,Anthony L.; Cafferata,Robert; Keefer,Larry K., Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use.
Garvey, David S.; Schroeder, Joseph D.; Saenz de Tejada, Inigo, Imidazoline .alpha.-adrenergic receptor antagonist compounds in combination with nitric oxide donors, compositions and methods of use.
Keefer Larry K. (Bethesda MD) Hrabie Joseph A. (Frederick MD), Implants, prostheses, and stents comprising polymer-bound nitric oxide/nucleophile adducts capable of releasing nitric o.
Cooke John P. ; Schwarzacher Sverin ; Lim Tai T.,SGX ; Yeung Alan C., Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury.
Cooke John P. ; Schwarzacher Sverin ; Lim Tai T.,SGX ; Yeung Alan C., Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury.
Killat George R. (Midland MI) Tomalia Donald A. (Midland MI), Ion exchange/chelation resins containing dense star polymers having ion exchange or chelate capabilities.
Herzog, Jr., William R.; Pou, Sovitj; Rosen, Gerald M.; Zhao, Yi-Ju, Medical device coated with a polymer containing a nitric oxide releasing organometallic nitrosyl compound useful for the prevention of platelet aggregation.
Rosen Gerald M. ; Herzog ; Jr. William R. ; Pou Sovitj, Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosy.
Cheng,Heng Seng; Ngoh,Lek Heng; Yuan,Zheng, Method and system for enabling recovery of data stored in a computer network; a method and a system for recovering data stored in a computer network.
Meyerhoff, Mark E.; Reynolds, Melissa M.; Frost, Megan; Hwang, Sangyeul; Wu, Yiduo, Method of increasing biocompatibility of medical device by generating nitric oxide.
Gregory W. Endres, Method of preventing fouling organisms in marine environments and polymer-bound nitric oxide/nitric oxide-releasing compositions usable therefor.
Jeffrey E. Thomas, Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal.
Salzman Andrew L. ; Smith Daniel J. ; Szabo Csaba ; Brilli Richard J. ; Krafte-Jacobs Brian, Nitric oxide donor compounds and pharmaceutical compositions for pulmonary hypertension and other indications.
Robertson Towart GB; Jan Olof Gustav Karlsson NO; Lars Goran Wistrand SE; Hakan Malmgren SE, Nitric oxide releasing chelating agents and their therapeutic use.
Wink ; Jr. David A. ; Mitchell James B. ; Russo Angelo ; Krishna Murali C. ; Hanbauer Ingeborg ; Grisham Matthew B. ; Granger Daniel Neil, Nitric oxide releasing compounds as protective agents in ischemia reperfusion injury.
Joseph E. Saavedra ; Larry K. Keefer ; Peter P. Roller ; Miki Akamatsu, Nitric oxide-releasing 1-[(2-carboxylato)pyrrolidin-1-yl] diazen-1-ium-1,2-diolates and composition comprising same.
Hrabie, Joseph A.; Keefer, Larry K.; Arnold, Ernst V., Nitric oxide-releasing amidine diazeniumdiolates, compositions and uses thereof and method of making same.
Hrabie,Joseph A; Keefer,Larry K; Arnold,Ernst V, Nitric oxide-releasing amidine diazeniumdiolates, compositions and uses thereof and method of making same.
Hrabie, Joseph A.; Keefer, Larry K., Nitric oxide-releasing amidine—and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same.
Hrabie Joseph A. ; Keefer Larry K., Nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same.
Hrabie, Joseph A.; Keefer, Larry K., Nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same.
Hrabie, Joseph A.; Keefer, Larry K., Nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same.
Mitchell James B. ; Russo Angelo ; Krishna Murali C. ; Wink ; Jr. David A. ; Liebmann James E., Nitric oxide-releasing compounds to sensitive cancerous cells to chemotherapeutic agents.
Arnold, Ernst V.; Keefer, Larry K.; Hrabie, Joseph A., Nitric oxide-releasing imidate and thioimidate diazeniumdiolates, compositions, uses thereof and method of making same.
Fitzhugh Anthony L. ; Cheng Peiwen ; Saavedra Joseph ; Cafferata Robert ; Hendriks Marc,NLX ; Keefer Larry K. ; Tedeschi Eugene ; Verhoeven Michel L. P. M.,NLX, Nitric oxide-releasing metallic medical devices.
Fitzhugh, Anthony L.; Cheng, Peiwen; Saavedra, Joseph; Cafferata, Robert; Hendriks, Marc; Keefer, Larry K.; Tedeschi, Eugene; Verhoeven, Michel I. P. M., Nitric oxide-releasing metallic medical devices.
Rosen Gerald M. (Lutherville MD) Herzog ; Jr. William R. (Baltimore MD) Pou Sovitj (Baltimore MD), Nitric oxide-releasing nitroso compositions and methods and intravascular devices for using them to prevent restenosis.
David S. Garvey ; Joseph D. Schroeder ; Inigo Saenz de Tejada ES, Nitrosated and nitrosylated .alpha.-adrenergic receptor antagonist compounds, compositions and their uses.
David S. Garvey ; Joseph D. Schroeder ; Inigo Saenz de Tejada ES, Nitrosated and nitrosylated .alpha.-adrenergic receptor antagonist compounds, compositions and their uses.
Garvey David S. ; Schroeder Joseph D. ; Saenz de Tejada Inigo,ESX, Nitrosated and nitrosylated .alpha.-adrenergic receptor antagonist compounds, compositions and their uses.
Garvey David S. ; Schroeder Joseph D. ; de Tejada Inigo Saenz,ESX, Nitrosated and nitrosylated .alpha.-adrenergic receptor antagonist compounds, compositions and their uses.
David S. Garvey ; Joseph D. Schroeder ; Inigo Saenez de Tejada ES; Ricky D. Gaston ; Tatiana E. Shelekhin ; Tiansheng Wang, Nitrosated and nitrosylated .alpha.-adrenergic receptor antagonist, compositions and methods of use.
Stamler Jonathan (Boston MA) Loscalzo Joseph (Dedham MA) Simon Daniel (Waban MA) Singel David (Arlington MA), Nitrosylation of protein SH groups and amino acid residues as a therapeutic modality.
Stamler Jonathan ; Loscalzo Joseph ; Simon Daniel ; Singel David, Nitrosylation of protein SH groups and amino acid residues as a therapeutic modality.
Stamler, Jonathan; Loscalzo, Joseph; Simon, Daniel; Singel, David, Nitrosylation of protein SH groups and amino acid residues as a therapeutic modality.
Saavedra, Joseph E.; Keefer, Larry K.; Srinivasan, Aloka; Rice, William G.; Ji, Xinhua; Bogdan, Christian, O2-arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1-[(2-carboxylato) pyrrolidin-1-yl] diazen-1-ium-1,2-diolates.
Saavedra, Joseph E.; Keefer, Larry K.; Srinivasan, Aloka; Bogdan, Christian; Rice, William G.; Ji, Xinhua, O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates.
Waterhouse, David J.; Kapur, Preeya; Keefer, Larry K.; Hrabie, Joseph A.; De Rosa, Frank, Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same.
Waterhouse,David J.; Kapur,Preeya; Keefer,Larry K.; Hrabie,Joseph A.; De Rosa,Frank, Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same.
Keefer Larry K. (Bethesda MD) Hrabie Joseph A. (Frederick MD), Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biologic.
Keefer Larry K. (Bethesda MD) Hrabie Joseph A. (Frederick MD) Saavedra Joseph E. (Thurmont MD), Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods o.
Keefer Larry K. ; Hrabie Joseph A., Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods o.
Keefer Larry K. ; Hrabie Joseph A., Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same.
Smith Daniel J. (Stow OH) Chakravarthy Debashish (Garrettsville OH) Keefer Larry K. (Bethesda MD), Polysaccharide-bound nitric oxide-nucleophile adducts.
Frank Dobert DE; Paul Wagner DE; Alexander Klausener DE; Wolfgang Eymann DE; Rolf Feller DE, Process for preparing trimethylol compounds and formic acid.
Stamler Jonathan (Chapel Hill NC) Loscalzo Joeseph (Dedham MA) Slivka Adam (Randolph MA) Simon Daniel (Waban MA) Brown Robert (Natick MA) Drazen Jeffrey (Winchester MA), S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof.
Stamler Jonathan (Chapel Hill NC) Loscalzo Joseph (Dover MA) Slivka Adam (Randolph MA) Simon Daniel (Waban MA) Brown Robert (Natick MA) Drazen Jeffrey (Winchester MA), S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof.
Arnold, Ernst V.; Doletski, Blaine G.; Dunn, Thomas M.; Raulli, Robert E.; Mueller, Edward P.; Benedek, Karen R.; Murville, Marie-Louise, Sterilization system and device.
Cooke John P. (Palo Alto CA) Dzau Victor J. (Los Altos Hills CA) Gibbons Gary H. (Palo Alto CA), Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity.
Lee, Jung-Joon; Lee, Jeong-Hyung; Kim, Hang-Sub; Hong, Young-Soo; Hwang, Bang-Yeon, Use of diterpene compound as a therapeutic agent of inflammation, immune disease or cancer.
Miller,Chris; Ghaffari,Abdi; Ardakani,Ali; Murray,Bruce; Hole,Doug, Use of exogenous gaseous nitric oxide in the treatment and disinfection of biofilms.
Mitchell James B. (Damascus MD) Russo Angelo (Bethesda MD) Krishna Murali C. (Derwood MD) Wink ; Jr. David A. (Hagerstown MD) Liebmann James E. (Albuquerque NM), Use of nitric oxide releasing compounds as hypoxic cell radiation sensitizers.
Mitchell James B. ; Russo Angelo ; Krishna Murali C. ; Wink ; Jr. David A. ; Liebmann James E., Use of nitric oxide releasing compounds to protect noncancerous cells from chemotherapeutic agents.
Korthuis Ronald J. (Shreveport LA) Kong Lipu (Shreveport LA) Keefer Larry K. (Bethesda MD), Use of nitric oxide-releasing agents for reducing metastasis risk.
Mitchell James B. ; Russo Angelo ; Krishna Murali C. ; Wink ; Jr. David A. ; Liebmann James E., Use of nitric oxide-releasing compounds as hypoxic cell radiation sensitizers.
Jonathan S. Stamler ; Claude A. Piantadosi ; Mark W. Dewhirst, Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.